TITLE:
Dermatomyositis Post COVID-19 Vaccine: A Case Report
AUTHORS:
Giovana Gabriela Koptian, Dalianna Luise Andrade Souto Rodrigues, Luiz Felipe Adsuara de Sousa, Dawton Yukito Torigoe
KEYWORDS:
COVID-19, Vaccine, Dermatomyositis, Systemic Autoimmune Myopathies
JOURNAL NAME:
Open Journal of Rheumatology and Autoimmune Diseases,
Vol.12 No.2,
May
31,
2022
ABSTRACT: Dermatomyositis (DM) is a rare systemic autoimmune disease characterized
by symmetrical and predominantly proximal muscle weakness in the limbs,
associated with typical skin lesions. Autoimmune diseases have already been
described as an adverse effect of vaccines. Case-report: A 65-year-old
Caucasian female patient evolved, 5 days after the first dose of the AZD1222
vaccine against the COVID-19 virus, with skin lesions suggesting heliotrope and
Gottron’s sign, with partial improvement of the condition with use of topical glucocorticoids in the lesions. After two months,
the patient received the second dose of AZD1222 vaccine, and evolved with
proximal muscle weakness of upper and lower limbs, dysphagia, increase
of muscle enzymes, in addition to skin lesions compatible with heliotrope and
Gottron’s sign again. After treatment with pulse therapy with
methylprednisolone 1000 mg per day for three days and treatment with immunosuppressants, she
evolved with significant clinical improvement. Conclusions: This case-report
demonstrating an important chronological relationship between dermatomyositis and the vaccine AZD1222 alerts to the possibility
of the disease as an important adverse reaction of vaccine against
COVID-19 virus, as has been recently described by other authors.